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Background: Image-guidance maximizes the therapeutic index of brain irradiation by decreasing setup uncertainty.
As dose-volume data emerge defining the tolerance of critical normal structures responsible for neuroendocrine
function and neurocognition, minimizing clinical target volume (CTV) to planning target volume (PTV) expansion of
targets near these structures potentially lessens long-term toxicity.
Methods: We reviewed the treatment records of 29 patients with brain tumors, with a total of 517 fractions
analyzed. The CTV was uniformly expanded by 3 mm to create the PTV for all cases. We determined the effect of
patient specific factors (prescribed medications, weight gain, tumor location) and image-guidance technique on
setup uncertainty and plotted the mean +/− standard deviation for each factor. ANOVA was used to determine
significance between these factors on setup uncertainty. We determined the impact of applying the initial three
fraction variation as custom PTV-expansion on dose to normal structures.
Results: The initial 3 mm margin encompassed 88% of all measured shifts from daily imaging for all fractions. There
was no difference (p = n.s.) in average setup uncertainty between CBCT or kV imaging for all patients. Vertical,
lateral, longitudinal, and 3D shifts were similar (p = n.s.) between days 1, 2, and 3 imaging and later fractions.
Patients prescribed sedatives experienced increased setup uncertainty (p < 0.05), while weight gain, corticosteroid
administration, and anti-seizure medication did not associate with increased setup uncertainty. Patients with targets
near OAR with individualized margins led to decreased OAR dose. No reductions to targets occurred with
individualized PTVs.
Conclusions: Daily imaging allows application of individualized CTV expansion to reduce dose to OAR responsible
for neurocognition, learning, and neuroendocrine function below doses shown to correlate with long-term
morbidity. The demonstrated reduction in dose to OAR in this study has implications for quality of life and provides
the motivation to pursue custom PTV expansion.
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The underlying goal of treating CNS malignancies is to
maximize tumor eradication while preserving parenchy-
mal brain function. Tilting the therapeutic index towards
eradicating tumor cells while protecting normal tissue
may be improved by reducing setup uncertainty. Image
guided radiation therapy (IGRT) has the potential to im-
prove accuracy through patient localization.* Correspondence: acspalding1@gmail.com
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reproduction in any medium, provided the orThe term clinical target volume (CTV) is defined in
the International Commission on Radiation Units and
Measurements (ICRU) Reports as “a tissue volume that
contains a gross tumor volume (GTV) which is the gross
palpable or visible/demonstrable extent + and location
of the malignant growth, and/or subclinical microscopic
malignant disease, which has to be eliminated. This vol-
ume has to be treated adequately in order to reach the
aim of therapy: cure or palliation” [1]. Planning target
volume (PTV) is defined as “a geometrical concept, and
it is defined to select appropriate beam sizes and beam
arrangements, taking into consideration the net effect ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in order to ensure that the prescribed dose is actually
absorbed in the CTV” [1]. The PTV is composed of two
factors: (1) the internal margin (IM) which relies on
temporal changes in position, volume, and shape of the
CTV and the (2) setup margin (SM) which accounts for
uncertainties in patient position and beam delivery that
is inherent with fractionated irradiation [2-4]. If the
margin between the CTV and PTV is too large, there is
a higher likelihood of excessive radiation to normal tis-
sue [5]. Inversely, if the margin is too small, an undesir-
able outcome may occur due to inadequate radiation of
the target tissue. The present study highlights patient
features and technical interventions which may play a
role in influencing the setup margin.
We tested the following hypotheses: 1) that the use of
days 1, 2, and 3 cone-beam CT scan or orthogonal kV
imaging predicted patient position during the treatment
course, 2) non technology related patient factors, specif-
ically a) prescribed medications b) weight gain, c) and
tumor location predicted setup uncertainty, and 3) appli-
cation of custom CTV to PTV expansion from the first
three fractions reduces dose to organs at risk (OAR).
Methods
Under an IRB-approved protocol and in compliance with
the Helsinki Declaration, we reviewed the treatment re-
cords of 29 patients with brain tumors immobilized with
an aquaplast mask and standard base plate or an S-frame
and aquaplast mask for simulation. The treatment plan-
ning CT with 1 mm neutral gantry axial slices was fused
with a gadolinium-enhanced MRI with 3 mm zero tilt
axial, coronal, and sagittal slices for target delineation.
The CTV was uniformly expanded by 3 mm to create the
PTV for all cases to minimize fusion errors. This approach
is similar to a phantom study shown to have an accuracy
of autofusion less than 0.5 mm [6]. Anatomic verification
of deep brain electrode placement based on CT/MRI fu-
sion has been shown to have accuracy of a similar magni-
tude [7]. OAR were contoured (temporal lobes, brainstem,
bilateral hippocampus, cochlea, hypothalamus, and pituit-
ary gland) and were used for inverse-planned static gantry
IMRT. The equipment utilized was a Varian linear acceler-
ator with orthogonal kilovoltage imagery.
All patients were treated with daily fractionated radi-
ation with the dose dependent on tumor histology: 21
patients with high grade glioma received 60 Gy in 30 frac-
tions; 4 patients with low grade glioma, 2 patients with
meningioma, and 2 patients with pituitary adenoma re-
ceived 50.4 Gy in 28 fractions. The number of beams and
angles was chosen based on tumor location and proximity
of OAR.
A total of 517 treatments were delivered with online
corrections made and recorded in the vertical, lateral,and longitudinal axis. The three dimensional vector of
uncertainty was calculated as the square root of the sum
of the squares of each axis:
3D shift ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Vertð Þ2 þ Latð Þ2 þ Longð Þ2
q
Patients found to have setup uncertainty less than 3 mm
were planned with the measured setup uncertainty, with
no change in optimization parameters. The setup uncer-
tainty was dependent on the localization. A bony match as
opposed to a soft tissue match was utilized since the base
of the skull served as a surrogate for intracranial targets.
We determined the effect of patient specific factors (pre-
scribed medications, weight gain, and tumor location) and
technical interventions on setup uncertainty, and plotted
the mean +/− standard deviation for each factor. Student’s
t-test was used to compare between groups.
Results
Image Guidance Modality and Setup Uncertainty
We first determined the influence of Cone Beam Com-
puted Tomography (CBCT) versus On Board Imaging
(OBI) imaging on patient set up variability. For each of
the 29 patients, shift data was recorded and analyzed for
both techniques. There was no difference between tech-
niques for shifts in the vertical (2+/−4 mm CBCT vs
2+/−2 mm OBI, p = 0.45), longitudinal (1.3+/−1.4 mm
CBCT vs 1.4+/− 1.4 mm OBI, p = 0.07), or three dimen-
sional (3.5+/−4.2 mm CBCT vs 3.6+/− 1.9 mm OBI,
p = 0.52) vector averages. There was a statistical differ-
ence in the lateral vector (1.4+/−1.6 mm CBCT vs 1.7+/−
1.5 mm OBI, p < 0.001) of small magnitude. We found no
clinically meaningful difference between the two imaging
modalities for evaluating translational setup uncertainty.
Setup Uncertainty First Three Treatment Days vs.
Subsequent Treatments via CBCT Image Guidance
We next determined whether the first three days of
IGRT would predict patient setup for subsequent frac-
tions. Patients underwent CBCT for the first three frac-
tions and remarked before the fourth fraction. As shown
in Figure 1, there was no statistical difference (p = NS) in
setup uncertainty between the first three days of treatment
and all subsequent treatments via CBCT image guidance.
We also analyzed post treatment images to quantify intra-
fraction motion. For 100 fractions, the mean difference
from pre-treatment to post-treatment images was 0.7 mm.
Immobilization Device and Setup Uncertainty
The use of an S-frame table extender allows the use of
additional beam angles to improve isodose conformality
and OAR sparing. However, there may be setup error in-
troduced due to flexion or insertion variability. We, there-
fore, compared the vertical, lateral, longitudinal, and three
Figure 1 Initial three IGRT fractions predict future patient position with CBCT. The vertical, lateral, longitudinal, and total three dimensional
setup uncertainty averages were plotted with +/− standard deviations for the first three days of treatment in black and all subsequent treatments
in white. Student’s t-test was used to determine significance between groups.
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via an aquaplast mask and base plate (N = 6) vs. an
aquaplast mask and S-Frame (N = 23) in Figure 2. S-
frame immobilization demonstrated a clinically signifi-
cant increase in setup uncertainty in the vertical axis
(2.5 +/− 3.7 mm S Frame vs. 1.3 +/− 0.9 mm for base
plate, p < 0.001) which contributed to the observed sig-
nificant difference in 3D setup variability.
Medications and Setup Uncertainty
The time from radiation CT simulation and planning to
the completion of radiation therapy can be up to eight
weeks for a 30 fraction course, and patients may changeFigure 2 S-frame extension contributes setup uncertainty compared
standard deviations for patients immobilized via aquaplast mask and base
mask and S-Frame in white. * Indicates p < 0.05 by Student’s t-test.during this time frame which may impact setup in a
thermoplastic mask. We measured the impact of cortico-
steroid administration (14 yes vs. 15 no), sedative adminis-
tration (11 yes vs. 18 no), anti-seizure administration (14
yes vs. 15 no), and weight change (23 stable vs. 6 with at
least a 10 lb gain) on setup uncertainty. Patient medication
history data were reviewed, and the status for three pre-
scribed medications was recorded. There was no statistical
difference in the proportion of patients prescribed medica-
tions and those not prescribed medications (p = NS).
Neither steroid administration nor weight change was as-
sociated with differences in setup variability. However, as
shown in Figure 3, patients administered sedatives hadwith base plate immobilization. Setup uncertainties with +/−
plate are demonstrated in black and those immobilized via aquaplast
Figure 3 Influence of sedatives on setup uncertainty. Setup uncertainty data in the vertical, lateral, longitudinal, and total three dimensional
setup uncertainty were plotted with +/− standard deviation. Setup uncertainty was statistically significant in patients who were prescribed
sedatives, shown in white (* p < 0.05).
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for non-sedated vs. 4.1+/−3.8 mm for sedated patients).
Those receiving anti-seizure medications had statistically
decreased setup uncertainty in the vertical, lateral, and
longitudinal axes of minimal clinical magnitude of less
than 0.5 mm in each vector.
Tumor Location and Setup Uncertainty
We hypothesized that central tumors would have less
setup uncertainty since rotational errors would not
influence location as opposed to lateral tumors. WeFigure 4 Tumor location influences setup uncertainty. The 3D vector +
P < 0.05 by ANOVA across all groups.classified targets (n = 29) according to location: Pituitary
(n = 3), frontal lobe (n = 8), temporal lobe (n = 7), occipi-
tal/posterior fossa (n = 9), and other (n = 4). There was
no statistical difference in the proportion of tumor loca-
tion (p = NS). Figure 4 shows the 3D vector uncertainty
average for the five groups with pituitary targets having
the least variability (2.8+/−2.0 mm) and temporal lobe tu-
mors demonstrating the highest (4.4+/−4.4 mm, p <0.05
across all groups by ANOVA). In this analysis, the dis-
tance from the center of the skull correlated with setup
uncertainty./− the standard deviation for each of the tumor locations are shown.
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Minimizing CTV to PTV expansion can lead to decreased
dose to normal tissues in close proximity to radiation tar-
gets. Three of the 29 patients had each fraction setup vari-
ation less than 3 mm, all three of them with central
targets. We applied the measured setup uncertainty and
applied their individual variation to generate a new smaller
PTV for each case. Their IMRT plans were reoptimized,
and as shown in Figure 5, application of patient-specific
CTV expansions results shift of DVH curves to the leftFigure 5 Planning with customized PTV allows decreased dose to crit
glioma underwent replanning with a CTV to PTV expansion of 1.5 mm as m
dose to the brainstem (blue, max from 5935 to 5550 cGy and mean from 4
and mean from 3892 to 3006 cGy), and temporal lobe (yellow, max from 6
tative isodose curves from original and reduced PTV, respectively.(arrows), decreasing dose to the brainstem, hippocampus,
and temporal lobe. The decrease in mean hippocampus
dose would in this case be predicted to preserve neurocog-
nitive function based on dose-volume relationships re-
ported previously [8].
Discussion
The treatment of intracranial malignancies has been
greatly enhanced by the use of radiation [8,9]. The ul-
timate objective is to administer a dose localized at theical normal structures. A. A patient with a centrally-located malignant
easured by IGRT in the first three days of treatment. This decreased
153 to 3596 cGy), hippocampus (orange, max from 6052 to 5761 cGy
550 to 6311 cGy and mean from 2623 to 2205 cGy). B. Axial represen-
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normal tissue, thus, minimizing the likelihood of long-
term neurocognitive deficits. Reducing the clinical target
volume has been shown to be adequate for tumor con-
trol with the intention of diminishing the potential cog-
nitive side effects inherent with radiation therapy [10].
The use of three-dimensional conformal radiation ther-
apy has been effective in increasing tumor control and
in reducing acute side effects [11].
The determination of the setup uncertainty prior to
the initiation of radiation plays an important role in the
treatment of CNS malignancies. Daily setup variation may
be underrecognized and may have an adverse impact, in-
cluding target underdose and normal structures receiving
a higher dose than anticipated [12,13]. Daily localization
based on cone beam CT imaging may reduce the required
setup margin lessening normal tissue exposure to radi-
ation [14]. Patient motion during treatment may affect the
dose to critical structures and, therefore, establishing risk
volumes are recommended to accurately ascertain the
dose administered to normal tissues [3].
Closely monitoring the target volume is vital during
radiation therapy to ensure that the doses to the target
and normal tissues are not altered which may have dele-
terious repercussions [15]. Beltran et al. have demon-
strated that the target volume during radiation therapy
in craniopharyngioma may increase and decrease (−20.7%
to 82%), stressing that surveillance imaging is necessary to
determine the appropriate dose to the target volume while
at the same time closely observing the amount to the nor-
mal tissue [15]. Beltran et al. have also recommended daily
localization which decreases the PTV margin and mini-
mizes insufficient tumor coverage due to setup uncertain-
ties [2]. In addition, a decrease in the CTV margin lessens
the dose directed to normal cerebral tissues [2].
Several studies have addressed daily setup variability in
the treatment of head and neck cancer patients using
conventional mask immobilization. Hong et al. showed a
3.33 mm absolute average daily setup error in any single
dimension while other studies have reported a range of
3–5 mm in head and neck setup variation using weekly
portal film measurements [12,16,17]. The patients in the
current study were either immobilized with an aquaplast
mask and either a base plate or S-frame. In our study,
immobilization with an S-frame significantly increased
setup uncertainty (3D p < 0.001) primarily in the vertical
direction, consistent with flexion of the insert as it pro-
trudes beyond the head of the table. Beltran et al. re-
ported that the setup margin was smaller for those
patients who were treated under anesthesia [4]. In the
present study, setup uncertainty was statistically signifi-
cant in patients who received sedatives (3D p < 0.001).
We hypothesize that patients at risk for claustrophobia
requiring oral sedation in fact would have demonstratedlarger variation without sedation, and in our study the
sedation was unable to completely ameliorate their anx-
iety. Patients prescribed either steroids or anti-seizure
medications demonstrated no statistical difference in
setup uncertainty.
We have shown that there was no statistical difference
in setup uncertainty between CBCT and OBI imaging
modalities. In addition, setup uncertainty was not signifi-
cant for the first three days of treatment versus all sub-
sequent treatment days via CBCT guidance. The first
three days of CBCT predicted setup uncertainty for sub-
sequent treatments and permitted customized CTV to
PTV expansion. Patient weight gain of greater than ten
pounds was not associated with increased setup uncer-
tainty. The data demonstrated that patients with a tumor
located in the temporal lobe experienced greater setup
uncertainty whereas those with pituitary tumors showed
the least setup uncertainty.Conclusion
Setup uncertainty in the course of radiation treatment
may be influenced by several factors, including the
immobilization device utilized in therapy, specific medica-
tions, and certain tumor locale. To minimize the setup
uncertainty, various institutions have instituted a policy of
daily and continuous evaluation of interfraction and intra-
fraction motion for all head and neck cancer patients
undergoing intensity-modulated radiation therapy [12,18].
Image-guidance potentially maximizes the therapeutic
index of brain irradiation by minimizing setup uncer-
tainty. Custom CTV to PTV expansion results in a re-
duced dose administered to the OAR which diminishes
the possibility of developing neurocognitive, learning,
and neuroendocrine deficits.
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